Who Owns Lakefront Biotherapeutics Stock?
NASDAQ: LKFTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 24.14%
- Held by insiders
- 26.43%
- Institutional holders
- 108
- Institutions 24.1%
- Insiders 26.4%
- Public and other 49.4%
Who owns Lakefront Biotherapeutics stock?
Institutional investors own about 24.1% of Lakefront Biotherapeutics's shares, spread across 108 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 26.43% of LKFT.
The largest institutional holders are Gilead Sciences Inc (25.35%), Tang Capital Management, LLC (5.75%) and Madison Avenue Partners, LP (5.23%). Together, the top 10 institutions control 46.8% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their LKFT positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of LKFT
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Gilead Sciences Inc | 16.71M | 25.35% | 0.0% |
| Tang Capital Management, LLC | 3.79M | 5.75% | 0.0% |
| Madison Avenue Partners, LP | 3.45M | 5.23% | +39.9% |
| Prosight Management, Lp | 2.00M | 3.03% | -2.2% |
| EcoR1 Capital, LLC | 1.67M | 2.53% | 0.0% |
| Ameriprise Financial, Inc. | 1.27M | 1.93% | -10.7% |
| UBS Group AG | 647.52K | 0.98% | +285.1% |
| DME Capital Management, LP | 482.75K | 0.73% | 0.0% |
| Renaissance Technologies, LLC | 424.70K | 0.64% | +4.1% |
| Blackrock Inc. | 394.01K | 0.60% | +16.5% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of LKFT
| Fund | Shares | % Held |
|---|---|---|
| Columbia Funds Series Trust-Columbia Overseas Value Fund | 595.59K | 0.90% |
| iShares Trust-iShares Biotechnology ETF | 339.10K | 0.51% |
| Columbia Fd.s Varbl Series TRT II-Columbia Varbl PORT. - Overseas Core | 280.32K | 0.43% |
| ALPS ETF TRUST-ALPS Medical Breakthroughs ETF | 80.03K | 0.12% |
| American Century ETF Trust-Avantis International Equity ETF | 30.45K | 0.05% |
| VALIC Co I-International Value Fund | 22.50K | 0.03% |
| Trust for Professional Managers-ActivePassive International Equity ETF | 19.65K | 0.03% |
| Steward Funds Inc-Steward Values Enhanced International Fund | 16.57K | 0.03% |
| American Century ETF Trust-Avantis International Small Cap Equity ETF | 7.61K | 0.01% |
| Invesco Exch-Trd Fd. TRT II-Invesco NASDAQ Future Gen 200 ETF | 4.21K | 0.01% |
Frequently asked questions
Who is the largest shareholder of Lakefront Biotherapeutics?
Gilead Sciences Inc is the largest institutional shareholder of LKFT, owning 25.35% of shares outstanding (16.71M shares) as of its latest 13F filing.
What percentage of Lakefront Biotherapeutics is owned by institutions?
Institutions own about 24.1% of LKFT shares and 32.8% of the public float.
How much of Lakefront Biotherapeutics do insiders own?
Insiders, such as officers and directors, own about 26.43% of LKFT shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.